Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. announced that its management will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston. The company is a clinical-stage biotechnology firm dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, with its lead asset abdakibart recently showing positive Phase 2 data.

Avalo Therapeutics, Inc. announced its upcoming inclusion in the small-cap Russell 2000® Index and the broad-market Russell 3000® Index. This change will be effective after the close of U.S. equity markets on June 26, 2026. The company, a clinical stage biotechnology firm, develops therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, with its lead asset abdakibart recently showing positive Phase 2 data.

Avalo Therapeutics, Inc. announced the appointment of Ron Philip to its Board of Directors. Mr. Philip brings over 30 years of biopharmaceutical leadership, including significant commercial and strategic execution experience, having guided multiple companies through product launches and billion-dollar exits. His expertise is expected to be invaluable as Avalo advances abdakibart, following positive Phase 2 results, into Phase 3 for hidradenitis suppurativa (HS).

Avalo Therapeutics, Inc. announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, with plans for Investigational New Drug (IND) submission in the first half of 2027. The company also posted an updated investor presentation. This news follows positive topline data from their Phase 2 LOTUS study for abdakibart in moderate-to-severe hidradenitis suppurativa (HS).

Avalo Therapeutics, Inc. announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, with plans to submit an Investigational New Drug (IND) application in the first half of 2027. AVTX-010 is designed to extend dosing intervals and has potential for hidradenitis suppurativa (HS) and other inflammatory disorders, building on the positive Phase 2 data of abdakibart. The company also plans to advance abdakibart into a pivotal Phase 3 registrational program, supported by recent financing and productive engagement with the FDA for AVTX-010.

Avalo Therapeutics, Inc. amended employment agreements for its Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, and Chief Business Officer, modifying severance and change-in-control benefits. Under normal termination without cause or for good reason, executives will receive 12-18 months of base salary, bonuses, and COBRA coverage, with full vesting of pre-effective date options. In a change-in-control scenario, benefits include 1.0x-1.5x base salary plus 1.0x target bonus, full equity acceleration, and extended option exercise periods. Additionally, the company exchanged 4,294.675 shares of Series C Preferred Stock for new Series C-1 Preferred Stock with an accredited investor, removing a beneficial ownership limit and allowing the investor to increase their stake from 4.99% to 9.99% of common stock.

Avalo Therapeutics held its 2026 Annual Meeting of Stockholders on June 2, 2026. Stockholders approved the election of seven directors to the Board and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Additionally, the Second Amended and Restated 2016 Employee Stock Purchase Plan was approved.

Avalo Therapeutics, Inc. announced it granted an inducement award consisting of an option to purchase 34,000 shares of its common stock to one new employee. The award, approved by the Compensation Committee, was granted on May 21, 2026, with an exercise price of $16.60 per share. The options will vest 25% on the one-year anniversary of the employee's start date, with the balance vesting monthly over 36 months, subject to continued service.

Avalo Therapeutics, a clinical-stage biotechnology company, completed a follow-on offering on May 7, 2026, raising approximately $405.0 million in net proceeds. This capital raise, which included common stock and pre-funded warrants, significantly bolsters the company's liquidity, following positive Phase 2 clinical trial data for its lead asset, abdakibart. For the three months ended March 31, 2026, the company reported a net loss of $19.6 million and negative cash flows from operations of $17.7 million.

Avalo Therapeutics announced positive topline Phase 2 LOTUS trial results for abdakibart in moderate to severe hidradenitis suppurativa (HS), meeting its primary endpoint with significant HiSCR75 response rates. The company plans to advance abdakibart into a registrational Phase 3 program. Avalo also completed a public offering of equity securities, raising gross proceeds of $431.3 million, which is expected to fund operations into 2029. For Q1 2026, the company reported a net loss of $19.6 million and cash, cash equivalents, and short-term investments of $82.0 million as of March 31, 2026, prior to the recent financing.